Archive
531 articles, sorted by publication time.
The varicella vaccine is far from a new technology, but dosing, protection, and immunization policy continue to shape public health choices. GC Biopharma’s new trial will move its two-dose product into a clinical stage closer to a potential market decision.
This is not simply another anticancer drug that blocks signals, but one that hands a cancer-driving protein over to the cell’s clearance system. Its approval moves the PROTAC concept from laboratory terminology into a formal treatment option for some patients with advanced breast cancer.
A collaboration announcement with limited information still reflects a shared anxiety in the antibody R&D industry: whether AI can shorten the trial-and-error period in early discovery is a question that ultimately must be answered by wet-lab experiments, reproducible data, and clinical pathways.
Protein structure prediction is moving from a research tool to the underlying engine of design platforms; it shortens the time needed to conceive candidate proteins, but it does not remove the barriers of wet-lab work, functional validation, and manufacturing scale-up.
This deal, worth up to $1.5 billion, is not just another ADC startup purchase by a major pharmaceutical company; it shows that competition in oncology drugs is moving from finding targets toward how to design more selective cytotoxic weapons.
If Pharvaris’s immediate-release formulation of deucrictibant is approved, management of sudden swelling attacks could shift from injections toward oral treatment; but in acute treatment for a rare disease, speed, safety, and real-world use settings will determine its place more than the form of administration.
For AMO-02 to become a registrational study in a rare pediatric neuromuscular disease, the key issues lie not only in the drug itself, but also in whether the trial endpoints, study population, and regulatory consensus can accommodate the complexity of the disease.
The absence of dose-limiting toxicity is a necessary signal for an early-stage cell therapy trial, but it does not amount to success; the real test will emerge in more complete safety data and anti-tumor responses.
A purchase move worth about $3.7 billion is not just financial news; it reflects how major pharmaceutical companies, amid patent expirations, R&D risk, and clinical evidence, are pulling external innovation into their own pipelines at a faster pace.
A filing submitted to a U.S. securities regulator has put Mira Pharma’s SKNY-1 back on the early-stage drug development stage; but from animal pharmacokinetic data to clinical efficacy, there remains a distance that cannot be crossed with an optimistic narrative.
Capital is pushing AI drug discovery into larger production lines, but what truly determines success may not be whether models can generate more molecules, but whether those candidates can pass through the narrow gates of experimentation, clinical development, and regulation.
The emergency use authorization for a COVID therapy will end in one year, signaling not only a change for a single product but also the gradual return of the pandemic response system to routine regulation and commercial reality.